- Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemiaPeng, Yanren; Guo, Danxia; Jiang, Sijie; Zheng, Hua*Chinese Medical Journal, 2022, 135(6): 730-731.
- A systematic review and meta-analysis of randomized controlled trials on the impact of ezetimibe on carotid intima-media thicknessKwon, Ryuk Jun; Son, Soo Min26th World Congress of Neurology (WCN), Montreal, CANADA, 2023-10-15 To 2023-10-19.
- Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysisIoannis, Farmakis; Ioannis, Doundoulakis; Areti, Pagiantza; Stefanos, Zafeiropoulos; Christina, Antza; Haralambos, Karvounis; George, GiannakoulasJournal of Cardiovascular Pharmacology, 2021, 77(3): 397-407.
会议论文
EFFICACY AND SAFETY OF EVOLOCUMAB IN CHINESE PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA: PRIMARY RESULTS OF THE HUA TUO _ CLINICAL TRIAL
20阅读
